Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones

被引:55
作者
Wispelwey, B [1 ]
机构
[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
关键词
D O I
10.1086/428053
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This review summarizes key data illustrating the clinical importance of pharmacodynamics, particularly among the fluoroquinolone family of antibacterials. Antibacterials are often divided into 2 groups - either time-dependent or concentration-dependent agents - on the basis of their mechanism of killing. Fluoroquinolones are concentration-dependent agents, and the parameter that correlates most closely with clinical and/or bacteriological success is the ratio of the area under plasma concentration curve (AUC) to the minimum inhibitory concentration ( MIC). The AUC: MIC threshold may vary by organism. For example, a ratio of at least 30 is often cited as optimal to achieve success against Streptococcus pneumoniae, whereas higher ratios ( > 100) are considered to be optimal for the treatment of infections due to gram-negative bacilli. Data are cited to suggest that the minimum ratio necessary to prevent the selection of resistant mutants may, in fact, be somewhat higher. Maximizing the AUC: MIC through the use of potent therapy may offer an opportunity to limit the development of resistance to fluoroquinolones.
引用
收藏
页码:S127 / S135
页数:9
相关论文
共 55 条
[1]   Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model [J].
Allen, GP ;
Kaatz, GW ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2606-2614
[2]   Clinical pharmacodynamics of quinolones [J].
Ambrose, PG ;
Bhavnani, SM ;
Owens, RC .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) :529-+
[3]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[4]   Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models [J].
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1665-1670
[5]  
Bédos JP, 1998, J PHARMACOL EXP THER, V286, P29
[6]   Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae [J].
Blondeau, JM ;
Zhao, XL ;
Hansen, G ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :433-438
[7]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[8]   Activities of newer fluoroquinolones against ciprofloxacin resistant Streptococcus pneumoniae [J].
Coyle, EA ;
Kaatz, GW ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1654-1659
[9]  
Craig W A., 1991, Antibiotics in Laboratory Medicine, P367
[10]   INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS [J].
CRAIG, WA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) :89-96